The dual PI3K/mTOR inhibitor BEZ235's efficacy in suppressing T cell induction and proliferation, and its potential to reduce GvHD severity while preserving antiviral responses, underscores its promise as a therapeutic target for preventing GvHD. Here, MTOR is linked to graft versus host disease.